Department of Medicine, Gustave Roussy, University of ParisSud, Villejuif, France; Medical Oncology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Department of Medicine, Gustave Roussy, University of ParisSud, Villejuif, France.
Crit Rev Oncol Hematol. 2015 Mar;93(3):293-303. doi: 10.1016/j.critrevonc.2014.10.015. Epub 2014 Nov 18.
Recent advances have been made in the molecular profiling of gynecological tumors. These discoveries have led to the development of targeted therapies that have the potential to disrupt molecular pathways involved in the oncogenesis or tumor progression. In this review, we highlight areas of recent progress in the field of membrane receptor inhibitors in gynecological malignancies and describe the biological rationale underlying the inhibition of these receptors. We will introduce drug immuno-conjugates, and give an update on the biological rationale and the clinical studies involving agents directed against EGFR, HER3, IGFR, MET, FGFR, NOTCH, and TRAIL. We also discuss the challenge facing these new therapies.
近年来，妇科肿瘤的分子谱分析取得了进展。这些发现导致了靶向治疗的发展，有可能破坏参与肿瘤发生或肿瘤进展的分子途径。在这篇综述中，我们强调了妇科恶性肿瘤中膜受体抑制剂领域的最新进展，并描述了抑制这些受体的生物学基础。我们将介绍药物免疫偶联物，并更新针对 EGFR、HER3、IGFR、MET、FGFR、NOTCH 和 TRAIL 的药物的生物学基础和临床研究。我们还讨论了这些新疗法面临的挑战。
